Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP, Hufnagl C, Brechelmacher S, Huemer F, Hackl H, Rinnerthaler G, Romeder F, Monzo Fuentes C, Morre P, Hauser-Kronberger C, Mlineritsch B, Greil R.
Gampenrieder SP, et al.
Pharmacogenomics J. 2017 Jul;17(4):344-350. doi: 10.1038/tpj.2016.25. Epub 2016 May 3.
Pharmacogenomics J. 2017.
PMID: 27139155